Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)

NCT04943068 is registered in ClinicalTrials.gov with Kwang Dong Pharmaceutical co., ltd. as lead sponsor.

NCT NCT04943068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04943068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
Lead sponsor
Kwang Dong Pharmaceutical co., ltd.
Phase
Phase 3
Overall status
Completed
Start date
May 10, 2021
Completion date
May 16, 2023
Enrollment
193 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypoactive sexual desire disorder